Investigation of the Effects of Quadratus Lumborum Block Applied to Patients in Kidney Transplant Surgery

Sponsor
Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT06011850
Collaborator
(none)
84
4.1

Study Details

Study Description

Brief Summary

This study aims to determine the most effective and long-lasting pain relief method for post-operative analgesia in kidney donor and recipient patients in kidney transplantation programme with the least invasive and least drug administration.

For this reason, it is planned to perform Quadratus lumborum plane block (QLB) in a group of patients who will be kidney donors and kidney recipients in kidney transplantation and who meet the American Society of Anesthesiologists (ASA) Physical Status Classification System 1-3 risk classification between the ages of 18-70 years, and to administer intravenous pain medication without block in another group. It is planned to include at least 84 patients in the Quadratus lumborum plan block (QLB) and Intravenous Analgesia group (IVA) without gender discrimination.

Postoperative Sedation-Agitation assessment and NRS (numeric pain scale) at 1st hour, 2nd, 6th, 12th and 24th hours, as well as possible side effects such as nausea, vomiting, shoulder pain, respiratory depression, bradycardia and hypotension, total amount of opioid analgesics consumed within 24 hours and duration of hospital stay will be observed and recorded.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Plane block ultrasound-guided intra-abdominal injection into the appropriate anatomical area

    • the injection will be administered immediately after general anaesthesia and intubation of the patient

    • to monitor compliance with the intervention The medical files and laboratory blood tests of the patients will be examined to determine whether there are any contraindications to the intervention (patients will be excluded in case of bleeding diathesis such as intra-abdominal fluid accumulation, cystic formation, International Normalized Ratio (INR) > 2 or thrombocytopenia).

    Blood pressure and heart rate values of the patient and the amount of fentanyl consumed will be recorded throughout the surgery.

    The level of sedation-agitation will be evaluated during extubation at the end of surgery.

    In the postoperative period, blood pressure, heart rate, pain scoring and the amount of opioid analgesic consumed will be recorded by the anaesthesiologist in the general surgery organ transplant unit and the general surgery specialist and nurses in the organ transplant service at the 1st, 2nd, 6th, 12th, and 24th hours.

    The patient's satisfaction level will be evaluated and recorded 24 hours after the operation.

    Study Design

    Study Type:
    Observational [Patient Registry]
    Anticipated Enrollment :
    84 participants
    Observational Model:
    Cohort
    Time Perspective:
    Cross-Sectional
    Official Title:
    Comparison of the Effects of Quadratus Lumborum Block (QLB) Applied for Preemptive Analgesia on Post-operative Pain in Recipients and Donors in Renal Transplantation Surgery With Intravenous Analgesic (IVA) Group
    Anticipated Study Start Date :
    Aug 28, 2023
    Anticipated Primary Completion Date :
    Dec 30, 2023
    Anticipated Study Completion Date :
    Dec 31, 2023

    Arms and Interventions

    Arm Intervention/Treatment
    Kidney Donor QLB Group

    Quadratus lumborum block (QLB) will be applied to the kidney donor in kidney transplant surgery immediately after induction of general anesthesia before the surgical incision is started.

    Kidney Donor Paracetamol Group

    In kidney transplantation surgery, 1000 milligrams of Paracetamol will be administered intravenously to the kidney donor before the surgical incision is started, immediately after induction of general anesthesia.

    Kidney Recipient QLB Group

    Quadratus lumborum block (QLB) will be applied to the kidney recipient in kidney transplant surgery immediately after induction of general anesthesia before the surgical incision is started.

    Kidney Recipient Paracetamol Group

    In kidney transplantation surgery, 1000 milligrams of Paracetamol will be administered intravenously to the kidney recipient before the surgical incision is started, immediately after induction of general anesthesia.

    Outcome Measures

    Primary Outcome Measures

    1. Assessment of pain (NRS) level [postoperative 1st, 2nd, 6th, 12th, 24th hours]

      The 11-point numeric scale ranges from '0' representing one pain extreme (e.g. "no pain") to '10' representing the other pain extreme (e.g. "pain as bad as you can imagine" or "worst pain imaginable"

    2. Total postoperative tramadol consumption [Within 24 hours postoperatively]

      milligrams

    Secondary Outcome Measures

    1. Sedation- agitation level [Will be assessed from immediately after extubation until transfer from the recovery room to the ward.]

      The Riker Sedation- Agitation Scale (RSAS): identifies seven levels of sedation and agitation, which range from dangerous agitation to deep sedation, with a thorough description of patient behavior. Riker sedation-agitation Scale:1- Unarousable, 2 -Very Sedated, 3- Sedated, 4 Calm and Cooperative, 5 -Agitated, 6 -Very Agitated, 7 -Dangerous Agitation

    2. Duration of first analgesic requirement [During the 24 hours postoperative period]

      Time in minutes from the patient's extubation to the first analgesic requirement

    3. Blood pressure measurement [It will be recorded 10 minutes before induction of anesthesia and every 15 minutes after intubation until the end of the operation.]

      Systolic, diastolic and mean arterial pressure measurements will be recorded by invasive arterial monitoring.

    4. Measurement of heart rate [It will be recorded 10 minutes before induction of anesthesia and every 15 minutes after intubation until the end of the operation.]

      The number of heart beats per minute obtained by electrocardiographic monitoring

    5. Amount of fentanyl consumed during the operation [During surgery]

      Micrograms of fentanyl consumed during surgery

    6. Patient satisfaction assessment [At the end of 24 hours postoperatively]

      Patients' satisfaction with the quality of pain management will be assessed at 24 hours postoperatively using the following scale: 1 = very dissatisfied; 2 = quite dissatisfied; 3 = moderate; 4 = quite satisfied; 5 = very satisfied.

    7. Nausea-vomiting [During the 24 hours postoperative period]

      Questioning about the presence/absence of nausea and/or vomiting in the postoperative period

    8. Length of hospital stay [It is assessed for up to 12 months from the date of surgery to the date of the first documented progression or the date of death from any cause, whichever comes first]

      Days of hospitalisation after the operation

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 70 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Patients aged 18-70 years,

    • American Society of Anesthesiologists (ASA) Physical Status Classification System I-III,

    • Being a volunteer kidney recipient or volunteer donor in a kidney transplant programme under general anaesthesia

    Exclusion Criteria:
    • Age <18 years or > 70 years

    • American Society of Anesthesiologists (ASA) Physical Status Classification System >III

    • body mass index (BMI) > 35 kg/m2

    • known allergy to local anaesthetics or paracetamol/tramadol

    • presence of preoperative chronic pain

    • presence of accumulated fluid or cystic formation in the abdomen

    • presence of coagulopathy

    • those who are unable to give written consent

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Fatma Acil, Principal Investigator, Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital
    ClinicalTrials.gov Identifier:
    NCT06011850
    Other Study ID Numbers:
    • 08.04.2023/484
    First Posted:
    Aug 25, 2023
    Last Update Posted:
    Aug 25, 2023
    Last Verified:
    Aug 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No

    Study Results

    No Results Posted as of Aug 25, 2023